Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis
Published online on: December 6, 2017
HTML 0 views
| PDF 0 views
Esophageal carcinoma is a common malignancy worldwide, with a low 5‑year survival rate. As the majority of cases are diagnosed at an advanced stage, there is an urgent need for an effective biomarker for early diagnosis of esophageal cancer patients. Surface‑enhanced laser desorption ionization time‑of‑flight mass spectrometry (SELDI‑TOF‑MS) was applied to detect the serum protein expression in esophageal cancer patients using ProteinChip software, and the results were analyzed and screened using Biomarker Patterns and SPSS16.0 software. The ELISA method was conducted to determine the concentration of anaphylatoxin C3a, which is one of the complement proteins, in the serum of esophageal cancer patients and non‑esophageal cancer participants. A total of 144 effective differential expression protein peaks in the window of 1‑10 kDa were obtained (P<0.05). M/Z 8,926.478 (P<10‑6) protein peak was employed as the diagnostic biomarker for esophageal carcinoma. This established diagnostic biomarker has a sensitivity of 95% (19/20) and an accuracy of 100% (19/19) for positive prediction. The results suggested that anaphylatoxin C3a may be a promising biomarker in the diagnosis of esophageal carcinoma, and may play a key role in promoting esophageal carcinogenesis.